The Efficacy in Navajo Infants of a Conjugate Vaccine Consisting ofHaemophilus influenzaeType b Polysaccharide andNeisseria meningitidisOuter-Membrane Protein Complex

Authors:
  • MWMark Wolff
    Mark Wolff
  • RRRaymond Reid
    Raymond Reid
  • MHMatt Hohenboken
    Matt Hohenboken
  • MBMassee Bateman
    Massee Bateman
  • JGJulius Goepp
    Julius Goepp
  • MCMargaret Cortese
    Margaret Cortese
  • DSDavid Sack
    David Sack
  • JHJanné Hill
    Janné Hill
  • WNWendy Newcomer
    Wendy Newcomer
  • LCLinda Capriotti
    Linda Capriotti
  • JSJeanne Smith
    Jeanne Smith

Abstract
Several conjugate vaccines against Haemophilus influenzae type b have been developed in the search for one that induces protection even in young infants. We evaluated the safety and efficacy of a conjugate vaccine that links the H. influenzae type b capsular polysaccharide to the outer-membrane protein complex (OMPC) of Neisseria meningitidis serogroup B. We conducted a double-blind, placebo-controlled trial in Navajo infants, who are at high risk for systemic infections caused by H. influenzae type b. The infants were randomly assigned to receive the first dose of vaccine or placebo at 42 to 90 days of age and the second at 70 to 146 days of age.

This publication has 15 references indexed in Scilit: